Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069543" target="_blank" >RIV/00216224:14110/13:00069543 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/13:43907542 RIV/61989592:15110/13:33144638 RIV/65269705:_____/13:#0002083 RIV/00179906:_____/13:10145985 and 4 more
Result on the web
<a href="http://dx.doi.org/10.1002/ajh.23508" target="_blank" >http://dx.doi.org/10.1002/ajh.23508</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ajh.23508" target="_blank" >10.1002/ajh.23508</a>
Alternative languages
Result language
angličtina
Original language name
Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
Original language description
Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months.The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Hematology
ISSN
0361-8609
e-ISSN
—
Volume of the periodical
88
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
790-797
UT code for WoS article
000323313500013
EID of the result in the Scopus database
—